As part of the plan, Amazon has agreed to purchase 100,000 electric delivery vans from vehicle manufacturer Rivian.Technologyread more
At least in terms of monetary policy, Pence says should be taking after other regions who keep their benchmark interest rates near zero.Delivering Alpharead more
The plan will allow Medicare to negotiate lower prices on as many as 250 drugs and apply those discounts to private health plans.Health and Scienceread more
Hedge fund titan Leon Cooperman said he's concerned about a shift to the left in the political landscape, which could harm the economy and the stock market.Delivering Alpharead more
Apple's big iOS 13 update for iPhones is out now and includes lots of new features. Here's how to install it on your phone and what devices are supported.Technologyread more
The pilot program will deliver food and beverage, over-the-counter medications and other items within minutes, the company said. Prescription deliveries will not be available.Health and Scienceread more
Check out the companies making headlines in midday trading:Market Insiderread more
The FDA's Office of Criminal Investigations opened a probe "shortly after" people started falling ill, Mitch Zeller, director of the FDA's Center for Tobacco Products, told...Health and Scienceread more
Investor Jim Chanos is betting against GrubHub, and said the food delivery company makes almost nothing per order.Delivering Alpharead more
Billionaire investor Leon Cooperman on Thursday said he believes that the Federal Reserve is "screwing the savers."Delivering Alpharead more
Datadog priced its stock at $27, selling 24 million shares and raising $648 million in its IPO.Technologyread more
GlaxoSmithKline is buying Novartis out of their consumer healthcare joint venture for $13 billion, taking full control of products including Sensodyne toothpaste, Panadol headache tablets, muscle gel Voltaren, and Nicotinell patches.
GSK's biggest move since Emma Walmsley became chief executive last year follows the British drugmaker's decision last week to quit the race to buy Pfizer's consumer healthcare business, endangering an auction the U.S. company hoped would bring in as much as $20 billion.
Consumer remedies sold over the counter have lower margins than prescription drugs, but they are typically very well known and durable brands with loyal customers.
"The proposed transaction addresses one of our key capital allocation priorities and will allow GSK shareholders to capture the full value of one of the world's leading consumer healthcare businesses," Walmsley said in a statement on Tuesday.
Although some pharmaceuticals groups have been keen to hold consumer care products, intense price competition online, mainly from Amazon, as well as cheaper store-brand products, have led others to doubt their stable returns longer-term.
The British group's shares jumped 6.3 percent, outperforming a 1.9 percent gain in the STOXX Europe 600 Health Care.
GSK said that as well as ending the Novartis venture it would start a strategic review of Horlicks and other consumer nutrition products, sparking another potential industry shake-up. The review will include an assessment of its shareholding in its Indian subsidiary.
"It (the deal) also removes uncertainty and allows us to plan use of our capital for other priorities, especially pharmaceuticals R&D," Walmsley said, adding that the purchase would boost adjusted earnings and cash flows.
Pfizer has been struggling to sell its consumer healthcare business after GSK and Reckitt Benckiser both dropped out of the bidding, while differences in price expectations have also hobbled German drugmaker Merck KGaA's attempts to sell its consumer products unit.
And GSKs call for bids for its consumer healthcare nutrition brands - with a regional focus on India - is likely to detract attention from Merck's asset, which relies heavily on sales of vitamins and dietary supplements in emerging markets.
Barclays analysts said Glaxo was paying less than 17 times expected 2018 core earnings for the joint venture stake, while sources have told Reuters that both Merck and Pfizer had asked for up to 20 times for their respective assets.
Yet analysts at Baader Helvea welcomed the cash price fetched by Novartis as "excellent news" for the Swiss company, whose shares opened 2.2 percent higher on the Swiss exchange.
Deutsche Bank analysts said the move decluttered Novartis's portfolio, but cautioned that the Swiss group was being too vague about what it would do with the cash.
"While our consumer healthcare joint venture with GSK is progressing well, the time is right for Novartis to divest a non-core asset at an attractive price," Novartis CEO Vas Narasimhan said.
Novartis said the money would be used by Novartis to expand its business organically as well as for bolt-on acquisitions.
In an interview before the deal was announced, Narasimhan ruled out large acquisitions by the Basel-based company.
"We really think we want to focus our M&A efforts on bolt on acquisitions that have either new technologies or products that fit into our core therapeutic areas," he told CNBC in an interview recorded on Sunday.
Under the 2014 deal to pool their consumer assets, Novartis had the right so sell its 36.5 percent stake to Glaxo from this month. The transaction is set to complete in the second quarter, subject to necessary approvals.